Bionano Genomics (BNGO) Competitors

$1.22 -0.02 (-1.61%)

As of 10:45 AM Eastern

BNGO vs. PRPO, AATC, DAIO, CLIR, and MSAI

Should you buy Bionano Genomics stock or one of its competitors? MarketBeat compares Bionano Genomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bionano Genomics include Precipio (PRPO), Autoscope Technologies (AATC), Data I/O (DAIO), ClearSign Technologies (CLIR), and MultiSensor AI (MSAI). These companies are all part of the "measuring and control equipment" industry.

How does Bionano Genomics compare to Precipio?

Bionano Genomics (NASDAQ:BNGO) and Precipio (NASDAQ:PRPO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

Precipio has a net margin of -3.57% compared to Bionano Genomics' net margin of -109.94%. Precipio's return on equity of -6.73% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-109.94%	-71.38%	-43.07%
Precipio	-3.57%	-6.73%	-4.49%

Precipio has lower revenue, but higher earnings than Bionano Genomics. Precipio is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.49	-$26.40M	-$4.37	N/A
Precipio	$24.05M	1.80	-$360K	-$0.47	N/A

Bionano Genomics has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Precipio has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

Bionano Genomics currently has a consensus target price of $6.00, suggesting a potential upside of 391.80%. Given Bionano Genomics' stronger consensus rating and higher probable upside, equities analysts plainly believe Bionano Genomics is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Bionano Genomics and Bionano Genomics both had 2 articles in the media. Precipio's average media sentiment score of 0.25 beat Bionano Genomics' score of -0.45 indicating that Precipio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bionano Genomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precipio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.4% of Bionano Genomics shares are held by institutional investors. Comparatively, 10.5% of Precipio shares are held by institutional investors. 0.7% of Bionano Genomics shares are held by company insiders. Comparatively, 16.6% of Precipio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Precipio beats Bionano Genomics on 8 of the 15 factors compared between the two stocks.

How does Bionano Genomics compare to Autoscope Technologies?

Autoscope Technologies (NASDAQ:AATC) and Bionano Genomics (NASDAQ:BNGO) are both small-cap measuring and control equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Autoscope Technologies has higher earnings, but lower revenue than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than Autoscope Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autoscope Technologies	$12.89M	2.31	$6.62M	$0.25	21.60
Bionano Genomics	$28.51M	0.49	-$26.40M	-$4.37	N/A

Autoscope Technologies has a net margin of 37.59% compared to Bionano Genomics' net margin of -109.94%. Autoscope Technologies' return on equity of 27.06% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autoscope Technologies	37.59%	27.06%	23.97%
Bionano Genomics	-109.94%	-71.38%	-43.07%

Autoscope Technologies has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

Bionano Genomics has a consensus price target of $6.00, suggesting a potential upside of 391.80%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts plainly believe Bionano Genomics is more favorable than Autoscope Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autoscope Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

11.4% of Bionano Genomics shares are held by institutional investors. 21.6% of Autoscope Technologies shares are held by company insiders. Comparatively, 0.7% of Bionano Genomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Bionano Genomics had 2 more articles in the media than Autoscope Technologies. MarketBeat recorded 2 mentions for Bionano Genomics and 0 mentions for Autoscope Technologies. Autoscope Technologies' average media sentiment score of 0.00 beat Bionano Genomics' score of -0.45 indicating that Autoscope Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Autoscope Technologies	Neutral
Bionano Genomics	Neutral

Summary

Autoscope Technologies beats Bionano Genomics on 9 of the 16 factors compared between the two stocks.

How does Bionano Genomics compare to Data I/O?

Data I/O (NASDAQ:DAIO) and Bionano Genomics (NASDAQ:BNGO) are both small-cap measuring and control equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

37.0% of Data I/O shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 2.6% of Data I/O shares are owned by insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Data I/O has a net margin of -41.85% compared to Bionano Genomics' net margin of -109.94%. Data I/O's return on equity of -54.33% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Data I/O	-41.85%	-54.33%	-36.75%
Bionano Genomics	-109.94%	-71.38%	-43.07%

Data I/O has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market.

Data I/O currently has a consensus target price of $5.11, indicating a potential upside of 61.20%. Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 391.80%. Given Bionano Genomics' higher possible upside, analysts clearly believe Bionano Genomics is more favorable than Data I/O.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Data I/O	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Data I/O has higher earnings, but lower revenue than Bionano Genomics. Data I/O is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Data I/O	$21.50M	1.38	-$5.24M	-$0.84	N/A
Bionano Genomics	$28.51M	0.49	-$26.40M	-$4.37	N/A

In the previous week, Data I/O had 2 more articles in the media than Bionano Genomics. MarketBeat recorded 4 mentions for Data I/O and 2 mentions for Bionano Genomics. Data I/O's average media sentiment score of 0.34 beat Bionano Genomics' score of -0.45 indicating that Data I/O is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Data I/O	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bionano Genomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Data I/O beats Bionano Genomics on 12 of the 16 factors compared between the two stocks.

How does Bionano Genomics compare to ClearSign Technologies?

ClearSign Technologies (NASDAQ:CLIR) and Bionano Genomics (NASDAQ:BNGO) are both small-cap measuring and control equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

24.0% of ClearSign Technologies shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 5.2% of ClearSign Technologies shares are owned by company insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ClearSign Technologies has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market.

In the previous week, ClearSign Technologies had 4 more articles in the media than Bionano Genomics. MarketBeat recorded 6 mentions for ClearSign Technologies and 2 mentions for Bionano Genomics. ClearSign Technologies' average media sentiment score of -0.22 beat Bionano Genomics' score of -0.45 indicating that ClearSign Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearSign Technologies	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bionano Genomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

ClearSign Technologies has higher earnings, but lower revenue than Bionano Genomics. ClearSign Technologies is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearSign Technologies	$5.23M	4.91	-$5.50M	-$0.99	N/A
Bionano Genomics	$28.51M	0.49	-$26.40M	-$4.37	N/A

Bionano Genomics has a net margin of -109.94% compared to ClearSign Technologies' net margin of -111.66%. ClearSign Technologies' return on equity of -61.24% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearSign Technologies	-111.66%	-61.24%	-45.80%
Bionano Genomics	-109.94%	-71.38%	-43.07%

ClearSign Technologies presently has a consensus target price of $20.00, indicating a potential upside of 321.05%. Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 391.80%. Given Bionano Genomics' higher probable upside, analysts clearly believe Bionano Genomics is more favorable than ClearSign Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearSign Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

ClearSign Technologies beats Bionano Genomics on 8 of the 14 factors compared between the two stocks.

How does Bionano Genomics compare to MultiSensor AI?

Bionano Genomics (NASDAQ:BNGO) and MultiSensor AI (NASDAQ:MSAI) are both small-cap measuring and control equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

In the previous week, Bionano Genomics had 1 more articles in the media than MultiSensor AI. MarketBeat recorded 2 mentions for Bionano Genomics and 1 mentions for MultiSensor AI. MultiSensor AI's average media sentiment score of 0.00 beat Bionano Genomics' score of -0.45 indicating that MultiSensor AI is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bionano Genomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MultiSensor AI	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MultiSensor AI has lower revenue, but higher earnings than Bionano Genomics. MultiSensor AI is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.49	-$26.40M	-$4.37	N/A
MultiSensor AI	$5.55M	2.30	-$11.71M	-$8.43	N/A

11.4% of Bionano Genomics shares are owned by institutional investors. Comparatively, 82.3% of MultiSensor AI shares are owned by institutional investors. 0.7% of Bionano Genomics shares are owned by company insiders. Comparatively, 50.8% of MultiSensor AI shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bionano Genomics currently has a consensus target price of $6.00, indicating a potential upside of 391.80%. MultiSensor AI has a consensus target price of $120.00, indicating a potential upside of 1,801.74%. Given MultiSensor AI's stronger consensus rating and higher probable upside, analysts clearly believe MultiSensor AI is more favorable than Bionano Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MultiSensor AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Bionano Genomics has a net margin of -109.94% compared to MultiSensor AI's net margin of -162.60%. MultiSensor AI's return on equity of -48.87% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-109.94%	-71.38%	-43.07%
MultiSensor AI	-162.60%	-48.87%	-41.13%

Bionano Genomics has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, MultiSensor AI has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

Summary

MultiSensor AI beats Bionano Genomics on 10 of the 17 factors compared between the two stocks.

Get Bionano Genomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNGO vs. The Competition

Export

Metric	Bionano Genomics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.01M	$3.37B	$6.39B	$12.49B
Dividend Yield	N/A	2.27%	2.76%	5.28%
P/E Ratio	-0.28	18.78	20.98	25.81
Price / Sales	0.49	330.26	559.63	87.99
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	0.37	7.11	10.41	7.22
Net Income	-$26.40M	$24.45M	$3.57B	$335.78M
7 Day Performance	4.27%	7.15%	4.39%	4.46%
1 Month Performance	0.83%	2.79%	1.84%	3.07%
1 Year Performance	-67.20%	64.11%	34.86%	37.79%

Bionano Genomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNGO Bionano Genomics	1.8824 of 5 stars	$1.22 -1.6%	$6.00 +391.8%	-66.7%	$14.01M	$28.51M	N/A	300
PRPO Precipio	1.2429 of 5 stars	$24.94 -4.2%	N/A	+148.8%	$44.59M	$25.83M	N/A	60
AATC Autoscope Technologies	N/A	$5.55 +0.9%	N/A	-26.3%	$30.31M	$12.89M	6.31	40	Gap Down
DAIO Data I/O	3.8342 of 5 stars	$3.02 -5.6%	$5.11 +69.2%	+23.3%	$28.37M	$18.57M	N/A	100
CLIR ClearSign Technologies	3.1232 of 5 stars	$4.41 -6.4%	$20.00 +353.5%	-21.8%	$25.48M	$5.23M	N/A	10	Negative News Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNGO) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bionano Genomics (BNGO) Competitors

BNGO vs. PRPO, AATC, DAIO, CLIR, and MSAI

How does Bionano Genomics compare to Precipio?

Summary

How does Bionano Genomics compare to Autoscope Technologies?

Summary

How does Bionano Genomics compare to Data I/O?

Summary

How does Bionano Genomics compare to ClearSign Technologies?

Summary

How does Bionano Genomics compare to MultiSensor AI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bionano Genomics (BNGO) Competitors

BNGO vs. PRPO, AATC, DAIO, CLIR, and MSAI

How does Bionano Genomics compare to Precipio?

Is BNGO or PRPO more profitable?

Which has stronger valuation and earnings, BNGO or PRPO?

Which has more volatility & risk, BNGO or PRPO?

Do analysts recommend BNGO or PRPO?

Does the media favor BNGO or PRPO?

Do institutionals and insiders have more ownership in BNGO or PRPO?

Summary

How does Bionano Genomics compare to Autoscope Technologies?

Which has higher valuation and earnings, AATC or BNGO?

Is AATC or BNGO more profitable?

Which has more volatility and risk, AATC or BNGO?

Do analysts rate AATC or BNGO?

Do insiders & institutionals hold more shares of AATC or BNGO?

Does the media refer more to AATC or BNGO?

Summary

How does Bionano Genomics compare to Data I/O?

Do insiders and institutionals have more ownership in DAIO or BNGO?

Is DAIO or BNGO more profitable?

Which has more risk & volatility, DAIO or BNGO?

Do analysts rate DAIO or BNGO?

Which has higher valuation and earnings, DAIO or BNGO?

Does the media favor DAIO or BNGO?

Summary

How does Bionano Genomics compare to ClearSign Technologies?

Do insiders & institutionals have more ownership in CLIR or BNGO?

Which has more risk and volatility, CLIR or BNGO?

Does the media refer more to CLIR or BNGO?

Which has higher earnings & valuation, CLIR or BNGO?

Is CLIR or BNGO more profitable?

Do analysts recommend CLIR or BNGO?

Summary

How does Bionano Genomics compare to MultiSensor AI?

Does the media prefer BNGO or MSAI?

Which has better earnings and valuation, BNGO or MSAI?

Do institutionals & insiders believe in BNGO or MSAI?

Do analysts rate BNGO or MSAI?

Is BNGO or MSAI more profitable?

Which has more risk and volatility, BNGO or MSAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools